Novartis stock trades steady as Q1 2026 revenue grows and Cosentyx expansion supports outlook

Novartis stock is backed by growing earnings, with the Swiss pharmaceutical group Novartis AG (ISIN CH0012005267) reporting that group net sales reached around $11.5 billion in Q1 2026, up roughly 7% from about $10.7 billion in Q1 2025 according to its investor information dated 18 April 2026, while core operating income increased to nearly $4.0 billion in the same quarter from approximately $3.6 billion a year earlier as shown in the companys investor materials.

Revenue up around 7 percent

According to Novartis investor materials released on 18 April 2026, the company reported Q1 2026 net sales of roughly $11.5 billion compared with around $10.7 billion in Q1 2025, representing an increase of about 7%, while core operating income for Q1 2026 rose to approximately $4.0 billion versus about $3.6 billion a year earlier, indicating earnings growth alongside sales expansion as shown by the firms quarterly highlights.

In the same Q1 2026 investor presentation, Novartis outlined that its Innovative Medicines division continued to account for the majority of net sales and that the company maintained a disciplined cost approach, which helped support the increase in core operating income; the materials also indicated that net income showed year-on-year improvement for Q1 2026 compared with Q1 2025, signaling that the operational leverage from revenue growth contributed to the overall profit picture.

Dividend and balance sheet metrics

Novartis investor information for its most recent full fiscal year shows that for 2025 the company generated net sales of roughly $46 billion and core operating income of about $16 billion, and that it proposed or paid a dividend of 3.40 Swiss francs per share for the 2025 financial year, continuing a pattern of regular shareholder distributions supported by its cash flow generation; this same investor context notes that Novartis maintains an investment-grade balance sheet and that net debt remains manageable relative to EBITDA, helping underpin its capital allocation strategy.

The 2025 annual figures in the Novartis investor materials also highlight that free cash flow for the year came in at more than $12 billion and that research and development spending reached a significant multibillion-dollar level, supporting a pipeline of immunology, oncology, and cardiovascular therapies; for investors watching Novartis stock, these full-year metrics frame the Q1 2026 numbers, since revenue growth and rising core operating income in Q1 2026 occur on top of an already sizable 2025 base, reinforcing that the current quarter is part of a broader expansion trend rather than a one-off result.

Cosentyx drives immunology growth

Cosentyx, a key immunology product for Novartis used to treat conditions such as psoriasis and psoriatic arthritis, is highlighted in the companys investor materials as one of the growth drivers in its Innovative Medicines portfolio, with reported double-digit sales growth in recent periods across major markets; the Q1 2026 investor context indicates that Cosentyx maintained a strong trajectory, contributing to the overall net sales increase compared with Q1 2025 and helping to diversify revenue away from older legacy drugs.

Novartis has emphasized in its pipeline and portfolio overview that Cosentyx continues to benefit from label expansions into additional indications, which potentially increase the addressable patient population and support sustained revenue growth; for example, investor information for 2025 and Q1 2026 describes how new data in rheumatology and dermatology settings underpins the commercial strategy for Cosentyx, aligning with the firms broader focus on immunology where it aims to consolidate franchise positions in both established and emerging treatment areas.

Novartis stock and market context

Based on recent market data from major financial portals, Novartis stock trades primarily on SIX Swiss Exchange with the ticker NOVN and also via ADR on the New York Stock Exchange, with the Swiss listing quoted in Swiss francs; as of 22 July 2026, Novartis shares on SIX were recently cited around CHF 88, situating the stock within a 52-week trading range that broadly spans from the low CHF 80s to the mid CHF 90s, which places the current level somewhat below the upper end of the range but above recent lows in that period.

Market capitalization figures from financial quote services indicate that as of 22 July 2026, Novartis carried an equity market value of approximately CHF 190 billion, reflecting its role as a major constituent of the Swiss Market Index and a significant global pharmaceutical player; taken together with the Q1 2026 net sales of roughly $11.5 billion and 2025 net sales around $46 billion, this market capitalization level suggests that investors continue to assign a substantial value to Novartis future cash flows from its marketed portfolio and pipeline, even though the share price has not recently been at the very top of its 52-week band.